2022 QSP Virtual Symposium

July 27-28, 2022


Virtual Symposium Overview

This virtual symposium brings together scientists interested in Quantitative Systems Pharmacology (QSP) in order to present and discuss contemporary approaches, including the challenges and the opportunities for advancing the science and practice of QSP.

The 2022 Symposium is our fifth annual and is a free 2‐day virtual event. 

We look forward to your participation!
Jim Gallo, 2022 QSP Symposium Organizer
Donald Mager, 2022 QSP Symposium Co-Organizer

On this page:


Wednesday, July 27

8:50 a.m. Welcome: James Gallo, PhD and Donald Mager, PharmD, PhD
9:00 a.m. Matthew Lazzara, PhD
“Data-driven computational modeling for the rational design of combination therapy for cancer”
9:45 a.m. Boris Kholodenko, PhD  
“Overcoming kinase inhibitor resistance and oncogenic RAS signaling”
10:30 a.m. Break
10:45 a.m. Fahima Nekka, PhD
“Dynamical systems analysis as a complementary tool to inform treatment outcomes of immune-oncology”
11:30 a.m. Ivana Bozic, PhD
"Dynamics of response and resistance to cancer therapy"
12:15 p.m. End Day 1

Thursday, July 28

9:00 a.m. Peter Sorger, PhD
“Re-evaluating oncology clinical trials using data science”
9:45 a.m. Matthew Riggs, PhD
“QSP to link learn/confirm with expand/understand in model-informed drug development“
10:30 a.m. Break
10:45 a.m. Amanda Randles, PhD
“Computational modeling to optimize treatment schedules for glioblastoma”
11:30 a.m. Trey Ideker, PhD
“Building the mind of cancer”
12:15 p.m. End Day 2


Ivana Bozic.
Ivana Bozic, PhD, Department of Applied Mathematics, University of Washington

Dr. Bozic is also an affiliate faculty member in the Herbold Computational Biology Program at the Fred Hutchinson Cancer Research Center in Seattle. She received her BSc and MA degrees in mathematics from the University of Belgrade, Serbia, and her PhD in mathematics from Harvard University. Her group at the University of Washington develops mathematical and computational models to study the evolutionary dynamics of cancer and its response to therapy. She is the recipient of the NSF CAREER Award and the Johnson & Johnson WiSTEM2D Scholars Award.

Trey Ideker.
Trey Ideker, PhD, University of California – San Diego

Dr. Ideker directs or co-directs the National Resource for Network Biology, and the Cancer Cell Map and Psychiatric Cell Map Initiatives. Trey received BS and MEng degrees in Computer Science from MIT and his PhD in Genome Sciences from the University of Washington. Trey is a pioneer in genomic, transcriptomic, and proteomic analysis and in the theory and practice of Systems Biology. He founded and continues to develop the widely used Cytoscape network analysis platform (>30,000 citations). Trey is on the Board of Scientific Advisors to the National Cancer Institute. Trey is an AAAS & AIMBE Fellow, and is a Web of Science Highly Cited Researcher (top 1% by citations).

Boris Kholodenko.
Boris Kholodenko, PhD, University College Dublin and Systems Biology Ireland

Dr. Kholodenko is a member of the Royal Irish Academy, and Adjunct Professor of Pharmacology, Yale University, New Haven, USA. He received a PhD in Biophysics from the Moscow Institute of Physics and Technology and a Dr.Sc. from Moscow State University.  He is a pioneer in the field of systems biology and provides mechanistic insights into cell signalling networks and their characteristic behaviours.

Matthew Lazzara.
Matthew Lazzara, PhD, Department of Chemical Engineering, University of Virginia

Matthew Lazzara received a BS in Chemical Engineering from the University of Florida and a PhD in Chemical Engineering from the Massachusetts Institute of Technology and remained at MIT for postdoctoral studies in the lab of Douglas Lauffenburger and was the recipient of an NIH Ruth L. Kirschstein National Research Service Award Postdoctoral Fellowship. The Lazzara Lab research employs a combination of experimental and computational methods to study problems in cell signaling. Current projects focus on the rational (model-driven) identification of combination therapies for cancer and on fundamental studies of the spatiotemporal regulation of cell signaling by phosphatases and receptor trafficking. 

Fahima Nekka.
Fahima Nekka, PhD, Université de Montréal

Dr. Nekka, received a PhD in mathematics in the field of fractal analysis, and has evolved her research into the areas of Pharmacometrics and Quantitative Systems Pharmacology (QSP).  Her projects span a whole range of therapeutic areas, involving fundamental aspects for methodologies development, their applications, and their translation to the end users at the academic, industrial and regulatory levels. She is an active mentor of a new generation of highly qualified personnel, trained between mathematics and pharmaceutical sciences. 

Amanda Randles.
Amanda Randles, PhD, Department of Biomedical Engineering, Duke University

Dr. Randles received her BS degree from Duke University and both her MS (Computer Sciences ) and PhD (Applied Physics) degrees from Harvard University. Her research in biomedical simulation and high-performance computing focuses on the development of new computational tools that we use to provide insight into the localization and development of human diseases ranging from atherosclerosis to cancer. Amongst her many awards, she has received the NSF CAREER award.  

Matthew Riggs.
Matthew Riggs, PhD, Metrum Research Group

Dr. Riggs received his BS degree in Pharmacy and PhD in Pharmaceutical Science from the University of Connecticut School of Pharmacy. Following a post-doctoral fellowship at GloboMax LLC (now ICON Development Solutions), Matthew worked for 5 years at Pfizer Global Research and Development and was an Associate Director and Clinical Pharmacology prior to joining MetrumRG as a Team Leader. At MetrumRG he leads research efforts to develop and integrate translational, quantitative, and systems pharmacology within model-driven therapeutics development. He is an ISoP Fellow and was the co-recipient of 2019 ISoP Innovation Award.

Peter Sorger, PhD.
Peter Sorger, PhD, Laboratory of Systems Pharmacology, Harvard Medical School

Dr. Sorger received his PhD from Trinity College in Cambridge; trained as a postdoctoral fellow at UCSF; and served as a Professor of Biology and Biological Engineering at MIT. Peter’s research uses mathematical and experimental approaches to study signal transduction networks controlling cell proliferation and death, dysregulation of these networks in cancer and inflammatory diseases and mechanisms of action of therapeutic drugs targeting signaling proteins.  The Sorger group also develops open-source software for analyzing biological networks and drug mechanism of action and it participates in multiple collaborative programs working to improve data access and reproducibility.

Questions? Contact Us

Jim Gallo, Empire Innovation Professor, Pharmaceutical Sciences: (jmgallo@buffalo.edu